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Abstract 
 
Eight receptors 1 – 8 comprising an L-Lysine scaffold modified at the N- and C- termini with 
aliphatic alkyl chains and N,N’-alkyl amides, respectively and bearing squaramide moieties on the 
amino acid side chain were synthesised by a combination of solid and solution phase chemistries 
and shown to complex various anions in 0.5% H2O in DMSO-d6 solution. All of the receptors were 
found to bind SO42-, Cl-, AcO- and BzO- via hydrogen bond or acid base interactions with the 
squaramide protons, however 1 was found to bind to SO42− via hydrogen bonds formed between the 
anion and both the squaramide and amide NH moieties. Moreover, modification of both the N- and 
C- termini of the amino acids with different alkyl substituents had a negligible effect on their anion 
binding properties while simultaneously conferring lipophilicities in a range that is optimal for 
molecules to behave as ‘drug-like’ systems as defined by Lipinski’s rule of five. The results of this 
study demonstrate the versatility of such amino acid receptors as building blocks in the field of 
anion recognition. 
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Introduction 
An area of intense focus within supramolecular chemistry in recent years has been the 
development of artificial receptors for anion binding, sensing, extraction and transport.1-5 In 
particular, significant effort has been directed towards the development of small molecules with the 
ability to selectively bind anions and facilitate their transport through lipid bilayers where the most 
effective anion transporters often show potent anticancer activity.1,6 
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In living systems, nature takes advantage of large peptides/proteins to successfully recognise and 
transport anions, using H-bonding interactions from various amino acid side chains (e.g. the OH 
groups of serine, threonine and tyrosine, the NH group in the indole moiety of tryptophan, and the 
guanidinium group of arginine) as well as from the amide backbone protons. However, synthetic 
peptide based anion receptors have received surprisingly little attention as membrane transport 
candidates. We have developed a number of highly efficient and selective anion receptors that can 
be constructed from a small number of amino acid building blocks to accommodate a variety of 
target anionic guests.7-10 The ability of these receptors to discriminate between anions has inspired 
us to examine their use as anion transporters and we have recently reported the design and synthesis 
of peptide based cryptands which we demonstrated to act as efficient SO42- transporters.10 One of 
the key features limiting the use of such receptors as effective transporters of anions across 
membranes is the need for molecules with both suitable binding affinity and lipophilicity. Indeed, 
recent reports by Gale and Quesada11,12 have highlighted the importance of receptor lipophilicity in 
transmembrane anion transport. We envisaged that the lipophilicity of our peptide based receptors 
could be readily tuned by the incorporation of various alkyl functionalities at the N- and C- termini. 
We chose to explore this using a series of amino acid receptors with squaramide–functionalised 
Lysine side chains, in which a variety of substituents were attached to the N- and C- termini to 
modulate receptor lipophilicity.  
The squaramide functional group has recently been exploited in supramolecular chemistry for 
the design of anion receptors,13-18 self-complementary molecular recognition motifs,19 and most 
recently by Gale et. al. where the squaramide motif was found to be a potent functionality for 
transmembrane anion transport of both chloride and bicarbonate.20 Notably, previous work indicates 
that the introduction of electron-withdrawing trifluoromethyl groups onto the squaramide aromatic 
substituents can be used to modify both lipophilicity and anion binding affinity.10,13 Herein we 
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report the synthesis of eight squaramide-containing receptors 1 – 8 (Figure 1) and a study of their 
anion complexation properties using 1H NMR spectroscopic methods. 
[insert Figure 1 here] 
 
Results and Discussion: 
Receptor Design and Synthesis: 
We chose L-Lysine (Lys) as a scaffold for the receptors as the side-chain of this amino acid can 
readily be functionalised with the squaramide anion binding motif and an amino acid of this type 
has previously been observed to bind to a range of anions.10 The N- and C- termini of the side-chain 
functionalised Lys scaffold provide suitable handles for the introduction of aliphatic alkyl chains 
and N,N’-dialkyl amides at the N- and C- termini, respectively, thereby allowing systematic 
modification of the receptor lipophilicity without changing the anion binding motif. Calculated 
log P (clogP) and total polar surface area (TPSA) values were calculated for receptors 1 - 8 using 
Spartan ‘10 (Ghose–Crippen model) after structure minimisation using AM1 semi-empirical 
methods and the results indicate that receptors 1 – 8 (Table 1) cover a range of lipophilicities with 
clogP values ranging from 1.45 - 5.76. Notably, many of the receptors lie within the boundaries 
defined by Lipinski’s rule of five, which dictates that a log P value ≤ 5 is optimal for molecules to 
behave as ‘drug-like’ systems; an important consideration in the context of the development of such 
anion receptor systems for biological applications.21  
The synthesis of 1 - 8 was carried out using an Fmoc solid phase peptide synthesis (Fmoc-SPPS) 
strategy on Wang resin (Scheme 1) with orthogonal allyloxycarbonyl (Alloc) protection of the side 
chain amino groups. Resin loading was achieved by treatment of Fmoc-Lys(Alloc)-OH with 
diisopropylcarbodiimide (DIC) in the presence of DMAP followed by reaction with preswollen 
Wang resin in DMF. Fmoc deprotection (20% piperidine/DMF) preceded coupling with the 
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appropriate alkyl carboxylic acid [(O-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate (HBTU)/iPr2NEt] to install the desired N-terminal alkyl chain. The Alloc 
group was then removed by treatment with Pd(PPh3)4 in the presence of acetic acid and 
morpholine22 before functionalisation of the side chain amine was achieved by reaction with either 
3-ethoxy-4-(phenylamino)cyclobut-3-ene-1,2-dione (1), 3-ethoxy-4-(4-
(trifluoromethyl)phenylamino)cyclobut-3-ene-1,2-dione (2) or 3-(3,5-
bis(trifluoromethyl)phenylamino)-4-ethoxycyclobut-3-ene-1,2-dione (3 – 8) to install the variously 
functionalised squaramide moieties. Once the desired scaffold had been assembled, cleavage from 
the solid support was effected by treatment with a solution of TFA/TIS/H2O (95/2.5/2.5; v/v) to 
yield the carboxylic acid precursors. The N,N’-dialkyl amide receptors (1 – 8) were successfully 
synthesised by coupling with the appropriate N,N’-dialkyl amine in the presence of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) and iPr2NEt before being purified by flash column 
chromatography to yield 1 - 8 in isolated yields of 44 - 65%.  
 
[insert Scheme 1 here] 
 
 
Anion Binding: 
In order to assess the anion binding properties of this family of receptors a number of 1H NMR 
spectroscopic titration experiments in 0.5% H2O in DMSO-d6 were conducted. Initially qualitative 
measurements with receptors 1 - 3 were undertaken using 1H NMR screening experiments in which 
10 eq. of a range of anions [Cl-, F-, SO42-, HSO4-, H2PO4-, AcO-, BzO-, NO3-, p-toluenesulfonate 
(OTs-) as their tetrabutylammonium salts] were added to the receptors in solution. These 
preliminary results indicated significant changes of the spectra of 1 - 3 in the presence of Cl-, F-, 
SO42-, H2PO4-, AcO-, BzO- culminating in large downfield shifts or disappearance of both of the 
squaramide NH protons (NHA and NHB) and, in some cases, the amide NH proton (NHC). 
	 6	
Conversely, only minor changes were observed in the presence of HSO4-, NO3- and TsO- suggesting 
little interaction of these anions with 1 – 3. For the trifluoromethylaniline functionalised squaramide 
derivatives 2 and 3, there was also a large degree of peak broadening observed for the NHA and 
NHB signals in the presence of F-, SO42-, H2PO4-, AcO- and BzO-  indicating that these receptors 
showed possible acid–base interactions with these anions (F-, AcO- and BzO-)23 or alternatively that 
more complex binding events (e.g proton-proton transfer between bound and unbound H2PO4-) or 
slow exchange processes (SO42-) are occuring.10,24 In contrast, the addition of Cl-, SO42-, AcO- and 
BzO- to receptor 1 resulted in downfield shifts of NHA and NHB as well as a large down field shift 
for the backbone amide NHC in the case of SO42-. 
In order to investigate the anion binding affinities more closely we conducted quantitative binding 
studies with 1 - 3 in the presence of Cl-, SO42-, AcO- and BzO-. Representative spectra for titration 
of 1 with AcO- and SO42- are shown in Figure 2, illustrating the significant downfield shifts of the 
squaramide proton signals and the varying response of backbone amide protons. Unfortunately, 
titration of 2 with SO42- and AcO- and 3 with SO42-, AcO- and BzO- led to peak broadening, 
preventing an association constant from being determined in these cases. In all other cases the 
observed changes to NHA and NHB were fitted to a 1:1 binding model using Hyperquad©25 to give 
apparent stability constants which are summarised in Table 1.   
Table 1 Summary of the anion binding affinities (Ka ), c log P and TPSA [Å2] values for  receptors 1–8.a, b 
 Ka (M-1) c log P PTSA (Å2) Receptor Cl- AcO- BzO- SO42- 
1 180 3600 3150 > 104 3.19 88.62 
2 209 -c 3715 -c 4.11 89.32 
3 383 -c -c -c 5.03 90.62 
4 380 -c -c -c 4.20 88.74 
5 417 -c -c -c 3.36 89.47 
6 457 -c -c -c 1.45 91.13 
7 389 -c -c -c 5.71 90.60 
8 394 -c -c -c 5.76 90.97 
a Determined at 300 K. Data was fitted to a 1 : 1 binding model. Ka values are an average obtained from monitoring 
both squaramide NH signals. Errors < 15%. b Anions added as their tetrabutylammonium salts. c Addition of SO42-, 
AcO- or BzO- resulted in peak broadening and prevented an association constant from being determined. 
 
A general trend was observed for Cl- binding where the receptor bearing the most electron 
withdrawing substituents, 3, was found to bind Cl- most strongly followed by 2 and finally 1 (3 + 
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Cl- Ka = 383 M-1, 2 + Cl- Ka = 209 M-1, 1 + Cl- Ka = 180 M-1). For titrations with AcO-, BzO- and 
SO42-, a comparison of relative anion affinities could only be made for receptor 1 (receptors 2 and 3 
exhibited behaviour suggesting deprotonation on addition of these more basic anions). Receptor 1 
was found to bind SO42- with an affinity too high to measure accurately by NMR and was also 
shown to exhibit higher affinity for SO42- than for AcO- or BzO- (1 + SO42- Ka > 104 M-1 while 1 + 
AcO- Ka = 3600 M-1 and 1 + BzO- Ka = 3150 M-1). Notably, the addition of SO42- resulted in a 
significant downfield shift (Δδ = 0.55) (Figure 2) of the amide proton of 1, indicating the possible 
formation of a hydrogen bonding interaction between this proton and SO42-. In contrast, the addition 
of Cl-, AcO- and BzO- to 1 resulted in a very minor shift of this proton (< 0.2 ppm), mirroring our 
results observed with dipeptide based anion receptors10 and suggesting that the higher affinity 
observed for binding of SO42- over that for other anions may be a result of the formation of an 
additional hydrogen bond to this anion. 
 
[insert Figure 2 here] 
 
We next wished to evaluate the effect of modification of the N- and C- termini of our amino acid 
based scaffold. Additional Cl- titrations were carried out using 4 - 8, to probe the effect of increased 
receptor lipophilicity on binding behavior while keeping the binding motif constant. For the series 3 
- 6 in which the N-terminal substituent was varied, a modest increase in affinity for Cl- was 
observed on decreasing the length of the chain from decanoyl (3: Ka = 387) to acetyl (6: Ka = 457) 
(Table 1), while receptors 3, 7 and 8 in which the C-terminal substituent was varied had essentially 
identical Cl- affinities (within experimental error) indicating that the C-terminal amide substituent 
had a neglible impact on binding affinity. These results indicate that the lipophilicity of these amino 
acid receptors can be tuned with negligible imact on binding affinity and opens the possibility of 
introducing other functionalities onto the amino acid based anion receptors or introducing amino 
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acid based receptors to larger receptor scaffolds or solid supports without having a detrimental 
effect on their anion recognition ability.  
 
Conclusions: 
In conclusion, we have developed an efficient strategy for the synthesis of amino acid based 
squaramide anion receptors 1 – 8 using a combination of solid and solution phase chemistries. We 
have demonstrated that receptors 1 – 8 can efficiently bind anions in aqueous DMSO solution with 
selective SO42− binding observed in the case of 1, which was attributed to hydrogen bonds being 
formed between the anion and both the squaramide and amide NH moieties. The ability to attenuate 
the molecular properties of these receptors without affecting their anion recognition properties has 
also been demonstrated and we envisage that this work will facilitate the potential use of peptide 
based anion receptors in biological or environmental applications. We are continuing to explore 
these and other aspects of peptide based anion complexation and the results of these studies will be 
reported in due course.  
 
 
Experimental Section: 
General Remarks: 
Optical rotations were obtained using a Perkin Elmer model 341 polarimeter at 589 nm and 20 °C, 
using the indicated spectroscopic grade solvent.  1H NMR (500 MHz) and 13C{1H} NMR (125 
MHz) were determined on a Bruker Avance DPX 500 spectrometer. Chemical shifts for 1H NMR 
are reported in parts per million (ppm) downfield shift from TMS using the residual solvent peak of 
dimethyl sulfoxide-d6 (δH 2.50 ppm) as internal references. The data are reported as chemical shift 
(δ), multiplicity (br = broad, s = singlet, d = doublet, t = triplet, dd = doublet of doublets, dt = 
doublet of triplets, m = multiplet), coupling constant (J Hz), relative integral and assignment where 
	 9	
possible. Chemical shifts for 13C{1H} NMR are reported in ppm, relative to the central line of a 
septet at δ = 39.51 ppm for dimethyl sulfoxide-d6. 
Infrared absorption spectra were recorded on a Bruker Alpha-E FT-IR spectrometer using 
attenuated total reflection (ATR) of a thin film. FT-IR are reported in wavenumbers (cm-1). HRMS 
(ESI) were obtained using a Bruker BioApex Fourier Transform Ion Cyclotron Resonance mass 
spectrometer (FTICR) with an analytical ESI source, operating at 4.7 T and reported as m/z (relative 
intensity). Commercial materials were used as received unless otherwise noted. Amino acids, 
coupling reagents and resins were obtained from Novabiochem or GL Biochem. Anhydrous CH2Cl2 
was obtained by distillation over CaH2 prior to use. Anhydrous DMF was purified by passage 
through neutral alumina using an Innovative Technology, Inc., PureSolv™ solvent purification 
system. HPLC grade DMF used for solid phase peptide synthesis was obtained from LabScan or 
Merck. Analytical TLC was performed using precoated silica gel plates (Merck Kieselgel 60 F254).  
Squarate monoesters were synthesised as previously described.15 
 
Synthesis: 
1. Loading of amino acid onto Wang resin. 
Under an atmosphere of nitrogen, Wang (100-200 mesh; resin capacity 1.1 mmol g-1) was swollen 
in a sinter-fitted syringe in anhydrous DMF for 1 h. Simultaneously, a solution of Fmoc-
Lys(Alloc)-OH (4 equiv. relative to resin capacity) was dissolved in anhydrous CH2Cl2 before DIC 
(2 equiv. relative to resin capacity) was added dropwise at 0°C and the resulting solution was stirred 
for 1 hr. The CH2Cl2 was removed under reduced pressure before the residue was dissolved in the 
minimum of anhydrous DMF. The resin was drained and treated with the amino acid solution and 
DMAP (0.1 equiv. relative to resin capacity) in anhydrous DMF and the resulting suspension was 
gently agitated at rt for 24 h under an atmosphere of nitrogen. The resin was drained and washed 
sequentially with DMF (5 × 10 mL), CH2Cl2 (5 × 10 mL) and DMF (5 × 10 mL). 
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2. N-terminal Fmoc deprotection.  
The resin-bound peptide was agitated in a solution of 10% piperidine in DMF (2 × 5 mL × 15 min) 
and then drained and washed sequentially with DMF (5 × 5 mL), CH2Cl2 (5 × 5 mL) and DMF (5 × 
5 mL). The resulting resin-bound amine was used immediately in the next coupling step. 
3. Estimation of resin loading.  
The drained Fmoc deprotection solution was diluted with a solution of 10% piperidine in DMF so 
that the maximum concentration of the fulvenepiperidine adduct was in the range of 2.5–7.5 × 10-5 
M. A sample of this solution  was transferred to two matched 1 cm quartz glass cuvettes and the 
UV-Vis absorbance at 301 nm was measured, using the solution of 10% piperidine in DMF as a 
reference. The absorbance values were used to calculate the loading, using ε = 7800 M-1 cm-1. 
4. Manual SPPS peptide coupling.  
Under an atmosphere of nitrogen, a solution of carboxylic acid (5 equiv. relative to loading), HBTU 
(5 equiv. relative to peptide) and iPr2NEt (10 equiv. relative to peptide) in anhydrous DMF was 
added to the resin and the resulting suspension was agitated at rt for 24 h. The resin was then 
washed sequentially with DMF (5 × 10 mL), CH2Cl2 (5 × 10 mL) and DMF (5 × 10 mL). 
5. Allyloxycarbonyl deprotection. 
The resin was swollen at rt for 15 min in CHCl3/morpholine/acetic acid (90:5:5; 10 mL). Pd(PPh3)4 
(0.15 equiv. relative to loading) was added and the suspension was agitated at rt for 3 hrs. The resin 
was drained and washed sequentially with  a solution of DMF/diethyldithiocarbamic acid-3-
water/triethylamine (25 mL; 225 mg; 250 µL) (5 × 5 mL), 0.5% triethylamine in DMF (5 × 10 mL), 
DMF (5 × 10 mL), CH2Cl2 (5 × 10 mL) and DMF (5 × 10 mL).  
6. Preparation of substituted N,N’-squaramides 
The resin was swollen at rt for 30 min in DMF before the addition of the appropriate squarate 
monoester (1.8 equiv. relative to loading) and triethylamine (3 equiv. relative to loading). The 
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suspension was agitated at 80°C for 24 hr, drained and washed sequentially with DMF (5 × 10 mL), 
CH2Cl2 (5 × 10 mL) and DMF (5 × 10 mL).  
7. Cleavage of intermediates from the resin.  
The resin was treated with a mixture of TFA/TIS/H2O (95/2.5/2.5; v/v) 5 mL) the resulting 
suspension was agitated at rt for 15 min. The solutions were drained and the resin was washed with 
CH2Cl2 (3 × 5 mL) before all washings were combined and the solvent was removed under reduced 
pressure to afford the crude product which was used without further purification.  
8. Preparation of  N,N’-alkyl amides 
To a stirred solution of the acid (1 equiv.) and the amine (5 equiv.) in anhydrous CH2Cl2 (0.15 M) 
was added EDC (2.5 equiv.) and iPr2NEt (5 equiv.) under an atmosphere of nitrogen. The resulting 
mixture was stirred at rt for 24 h before being quenched with sat. aq. NH4Cl solution (10 mL). The 
organic phase was washed with sat. aq. NH4Cl solution (2 × 10 mL), 0.2 M HCl (3 × 10 mL) and 
brine (10 mL). The organic layer was then dried over MgSO4 and the solvent was removed under 
reduced pressure. 
 
N-(1-(Dimethylamino)-6-(3,4-dioxo-2-(phenylamino)cyclobut-1-enylamino)-1-oxohexan-2-
yl)decanamide (1) 
Fmoc-Lys(Alloc)-OH was loaded onto Wang resin (500 mg, resin capacity 1.1 mmol g-1) according 
to general procedure 1. The N-terminal Fmoc protecting group was then removed (general 
procedure 2) and the appropriate carboxylic acid was coupled to the resin-bound amine according to 
the manual SPPS procedure 4. The side chain Alloc group was subsequently removed according to 
procedure 5 before installation of the appropriate squaramide moiety according to procedure 6. The 
resulting intermediate was cleaved from the resin according to general procedure 7 to afford the 
carboxylic acid derivative which was used in the final step without further purification. The N,N’-
alkyl amide functionality was finally introduced according to procedure 8 before subjection of the 
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crude material to flash chromatography eluting with 5% MeOH in EtOAc to yield  1 as a pale beige 
solid after lyophilisation (0.91 g, 59%). [α]20D = + 7.1 (c 0.17, MeOH); 1H NMR (500.13 MHz, 
DMSO-d6): 0.84 (t, J = 6.9 Hz, 3H), 1.20 – 1.61 (m, 20H), 2.07 (m, 2H), 2.80 (s, 3H), 3.01 (s, 3H), 
3.58 (br s, 2H), 4.70 (q, J = 8.3 Hz, 1H), 7.02 (t, J = 7.1 Hz, 1H), 7.33 (app t, J = 8.1 Hz, 2H), 7.43 
(d, J = 8.1 Hz, 2H), 7.62 (br s, NH), 7.97 (d, J = 8.6 Hz, NH), 9.61 (br s, NH); 13C NMR (125.76 
MHz, DMSO-d6): 14.4, 22.6, 22.6, 25.8, 29.1, 29.1, 29.2, 29.4, 30.8, 31.6, 31.8, 35.4, 35.6, 37.0, 
44.0, 48.3, 118.4, 123.0, 129.8, 139.6, 164.0, 169.7, 171.9, 172.4, 180.6, 184.4; HRMS (ESI) calcd. 
for C28H42N4O4Na [M + Na]+ 521.3098, found 521.3100.; IR (thin film) νmax 3286, 2926, 2854, 
1794, 1621, 1589, 1544, 1502, 1457 cm-1. 
 
N-(1-(Dimethylamino)-6-(3,4-dioxo-2-(4-(trifluoromethyl)phenylamino)cyclobut-1-
enylamino)-1-oxohexan-2-yl)decanamide (2) 
Procedure as for 1 above gave the desired compound as a pale beige solid after lyophilisation (0.137 
g, 65%). [α]20D = + 8.1 (c 0.12, MeOH); 1H NMR (500.13 MHz, DMSO-d6): 0.83 (t, J = 7.1 Hz, 
3H), 1.18 – 1.62 (m, 20H), 2.07 (m, 2H), 2.80 (s, 3H), 3.00 (s, 3H), 3.59 (br s, 2H), 4.70 (q, J = 8.6 
Hz, 1H), 7.60 (d, J = 7.8 Hz, 2H), 7.68 (d, J = 7.8 Hz, 2H), 7.73 (br s, NH), 7.97 (d, J = 7.8 Hz, 
NH), 9.93 (br s, NH); 13C NMR (125.76 MHz, DMSO-d6): 14.4, 22.5, 25.8, 29.1, 29.1, 29.4, 30.7, 
31.2, 31.6, 31.7, 35.5, 35.6, 37.0, 39.5, 39.6, 39.8, 40.0, 40.1, 40.2, 40.3, 40.4, 40.5, 40.6, 44.1, 
48.3, 118.3, 122.6, 123.5 (q, J = 33.6 Hz), 126.0, 127.1, 143.1, 163.3, 170.2, 171.8, 172.4, 185.2 ; 
HRMS (ESI) calcd. for C29H41N4O4F3Na [M + Na]+ 589.2972, found 589.2970.; IR (thin film) νmax 
3302, 2926, 2855, 1797, 1631, 1574, 1460, 1337, 1163, 1116, 1071 cm-1. 
 
N-(6-(2-(3,5-Bis(trifluoromethyl)phenylamino)-3,4-dioxocyclobut-1-enylamino)-1-
(dimethylamino)-1-oxohexan-2-yl)decanamide (3) 
	 13	
Procedure as for 1 above gave the desired compound as a pale beige solid after lyophilisation (0.20 
g, 63%). [α]20D = + 9.0 (c 0.13, MeOH); 1H NMR (500.13 MHz, DMSO-d6): 0.83 (t, J = 6.8 Hz, 
3H), 1.12 – 1.65 (m, 20H), 2.06 (m, 2H), 2.80 (s, 3H), 3.00 (s, 3H), 3.59 (br s, 2H), 4.68 (m, 1H), 
7.63 (s, 1H), 7.96 (d, J = 8.5 Hz, NH), 8.01 (br s, NH), 8.07 (s, 2H), 10.54 (br s, NH); 13C NMR 
(125.76 MHz, DMSO-d6): 14.4, 14.4, 22.5, 22.5, 25.8, 29.0, 29.1, 29.2, 29.3, 30.6, 31.5, 31.7, 35.4, 
35.6, 37.0, 44.1, 48.3, 115.0, 118.3, 123.6 (q, J = 274.7 Hz), 131.8 (q, J = 30.5 Hz), 141.8, 162.8, 
170.3, 171.8, 172.4, 180.7, 185.2 ; HRMS (ESI) calcd. for C30H40N4O4F6Na [M + Na]+ 657.2846, 
found 657.2843.; IR (thin film) νmax 3396, 2928, 2857, 1631, 1610, 1568, 1455, 1381, 1278, 1180, 
1134 cm-1. 
 
N-(6-(2-(3,5-Bis(trifluoromethyl)phenylamino)-3,4-dioxocyclobut-1-enylamino)-1-
(dimethylamino)-1-oxohexan-2-yl)octanamide (4) 
Procedure as for 1 above gave the desired compound as a pale beige solid after lyophilisation (0.104 
g, 65%). [α]20D = + 5.9 (c 0.15, MeOH); 1H NMR (500.13 MHz, DMSO-d6): 0.80 (t, J = 6.7 Hz, 
3H), 1.15 – 1.58 (m, 16H), 2.04 (m, 2H), 2.79 (s, 3H), 2.98 (s, 3H), 3.58 (br s, 2H), 4.67 (q, J = 8.5 
Hz, 1H), 7.63 (s, 1H), 7.68 (br s, NH), 7.95 (d, J = 8.4 Hz, NH), 8.01 (s, 2H), 10.14 (br s, NH); 13C 
NMR (125.76 MHz, DMSO-d6): 14.2, 14.3, 22.2, 22.5, 22.5, 25.4, 25.7, 28.8, 29.0, 30.7, 31.2, 31.3, 
31.6, 35.4, 35.6, 37.0, 44.2, 48.2, 115.1, 118.4, 123.7 (q, J = 277.3 Hz), 131.8 (q, J = 31.8 Hz), 
141.6, 162.7, 170.3, 171.8, 172.3, 180.8, 185.3; HRMS (ESI) calcd. for C28H36N4O4F6Na [M + Na]+ 
629.2533, found 629.2535.; IR (thin film) νmax 3280, 2928, 2861, 1796, 1631, 1580, 1461, 1434, 
1380. 
 
6-(2-(3,5-Bis(trifluoromethyl)phenylamino)-3,4-dioxocyclobut-1-enylamino)-2-hexanamido-
N,N-dimethylhexanamide (5) 
	 14	
Procedure as for 1 above gave the desired compound as a pale beige solid after lyophilisation (0.99 
g, 54%). [α]20D = + 3.5 (c 0.15, MeOH); 1H NMR (500.13 MHz, DMSO-d6): 0.80 (t, J = 7.0 Hz, 
3H), 1.15 – 1.61 (m, 12H), 2.06 (m, 2H), 2.81 (s, 3H), 3.00 (s, 3H), 3.60 (br s, 2H), 4.68 (q, J = 8.5 
Hz, 1H), 7.65 (s, 1H), 7.75 (br s, NH), 8.02 (s, 2H), 8.07 (d, J = 8.3 Hz, NH),10.20 (br s, NH); 13C 
NMR (125.76 MHz, DMSO-d6): 13.8, 21.7, 22.0, 24.9, 30.2, 30.8, 31.1, 34.9, 35.1, 36.5, 43.7, 47.8, 
114.6, 118.0, 123.1 (q, J = 270.9 Hz), 131.4 (q, J = 35.3 Hz), 141.1, 162.3, 169.8, 171.3, 171.8, 
180.3, 184.8; HRMS (ESI) calcd. for C26H32N4O4F6Na [M + Na]+ 601.2220, found 601.2220.; IR 
(thin film) νmax 3292, 2958, 2927, 1794, 1609, 1568, 1460, 1381, 1278, 1180, 1134. 
 
2-Acetamido-6-(2-(3,5-bis(trifluoromethyl)phenylamino)-3,4-dioxocyclobut-1-enylamino)-
N,N-dimethylhexanamide (6) 
Procedure as for 1 above gave the desired compound as a pale beige solid after lyophilisation (0.123 
g, 55%). [α]20D = + 3.4 (c 0.12, MeOH); 1H NMR (500.13 MHz, DMSO-d6): 1.31 – 1.64 (m, 6H), 
1.81 (s, 3H), 2.81 (s, 3H), 3.01 (s, 3H), 3.60 (br s, 2H), 4.68 (m, 1H), 7.65 (s, 1H), 7.71 (br s, NH), 
7.97 (d, J = 8.5 Hz, NH), 8.02 (s, 2H), 10.17 (br s, NH); 13C NMR (125.76 MHz, DMSO-d6): 22.1, 
22.3, 30.3, 31.2, 35.1, 36.5, 43.7, 48.0, 114.6, 118.0, 123.1 (q, J = 269.4 Hz), 131.3 (q, J = 36.7 
Hz), 141.2, 162.3, 168.9, 169.8, 171.3, 180.4, 184.8; HRMS (ESI) calcd. for C22H24N4O4F6Na [M + 
Na]+ 545.1594, found 545.1595.; IR (thin film) νmax 3292, 2943, 1795, 1611, 1563, 1458, 1380, 
1279, 1180, 1129. 
 
N-(6-(2-(3,5-Bis(trifluoromethyl)phenylamino)-3,4-dioxocyclobut-1-enylamino)-1-
(diethylamino)-1-oxohexan-2-yl)decanamide (7) 
Procedure as for 1 above gave the desired compound as a pale beige solid after lyophilisation (0.160 
g, 44%). [α]20D = + 3.5 (c 0.17, MeOH); 1H NMR (500.13 MHz, DMSO-d6): 0.83 (t, J = 7.0 Hz, 
3H), 0.98 (t, J = 7.0 Hz, 3H), 1.11 – 1.55 (m, 25H), 2.07 (m, 2H), 3.14 (m, 2H), 3.58 (d, J = 6.2 Hz, 
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2H), 4.62 (q, J = 8.7 Hz, 1H), 7.61 (s, 1H), 7.98 (d, J = 8.3 Hz, NH), 8.10 (s, 2H), 8.23 (br s, NH), 
10.82 (br s, NH); 13C NMR (125.76 MHz, DMSO-d6): 12.8, 13.9, 14.5, 22.0, 25.3, 28.6, 28.9, 30.2, 
31.2, 31.7, 34.9, 41.2, 43.6, 47.8, 114.3, 117.8, 123.2 (q, J = 272.8 Hz), 131.3 (q, J = 33.0 Hz), 
141.6, 162.5, 170.0, 170.7, 171.9, 180.3, 184.6; HRMS (ESI) calcd. for C32H44N4O4F6Na [M + Na]+ 
685.3159, found 685.3158.; IR (thin film) νmax 3291, 2928, 2857, 1793, 1609, 1563, 1451, 1331, 
1180, 1134 cm-1. 
 
N-(6-(2-(3,5-Bis(trifluoromethyl)phenylamino)-3,4-dioxocyclobut-1-enylamino)-1-oxo-1-
(piperidin-1-yl)hexan-2-yl)decanamide (8) 
Procedure as for 1 above gave the desired compound as a pale beige solid after lyophilisation (0.185 
g, 50%). [α]20D = - 3.5 (c 0.15, MeOH); 1H NMR (500.13 MHz, DMSO-d6): 0.83 (t, J = 6.9 Hz, 
3H), 1.17 – 1.57 (m, 26H), 2.07 (m, 2H), 3.39 – 3.58 (m, 6H), 4.69 (q, J = 8.5 Hz, 1H), 7.62 (s, 
1H), 7.98 (d, J = 8.7 Hz, NH), 8.10 (s, 2H), 8.19 (br s, NH), 10.74 (br s, NH); 13C NMR (125.76 
MHz, DMSO-d6): 13.9, 22.0, 24.0, 25.3, 25.3, 26.0, 26.1, 28.6, 28.6, 28.7, 28.7, 28.9, 30.1, 31.2, 
31.4, 35.0, 42.4, 43.6, 45.8, 47.6, 114.4, 117.7, 123.1 (q, J = 274.3 Hz), 131.4 (q, J = 31.7 Hz), 
141.5, 162.4, 169.4, 169.9, 171.7, 180.2, 184.6; HRMS (ESI) calcd. for C33H44N4O4F6Na [M + Na]+ 
697.3159, found 697.3160.; IR (thin film) νmax 3290, 2928, 2856, 1657, 1461, 1380, 1277, 1180, 
1133 cm-1. 
 
NMR Binding Studies 
NMR titrations were performed by additions of aliquots of the putative anionic guest as the 
tetrabutylammonium (TBA) salt (0.15 – 0.2 M), in a solution of the receptor (2.5 × 10-3M) in 0.5% 
H2O in DMSO-d6 to a 2.5 × 10-3 M solution of the receptor in 0.5% H2O in DMSO-d6. Typically, 
up to 9-12 equivalents of the anion were added to the solution. Both salt and receptor were dried 
under high vacuum prior to use. 1H NMR spectra were recorded on a Bruker Avance III 500 
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spectrometer at a frequency of 500.13 MHz and calibrated to the residual protio solvent peak in 
DMSO-d6 (δ = 2.50 ppm). Stack plots were made using MestReNova Version 6.0. Where possible 
and when the change in chemical shift was larger than 0.02 ppm, non-linear curve fitting of the 
experimentally obtained titration isotherms (equivalents of anion vs. chemical shift of the 
squaramide NH protons or amide NH protons) using the commercially available software program 
HypNMR® (Hyperquad® package) enabled the calculation of association constants (Ka/M-1) using a 
1:1 model. 
 
clogP Calculations 
Calculated log P (c log P) and total polar surface area (TPSA) values were calculated using Spartan 
‘10 (Ghose–Crippen model) for Windows (Wavefunction, Inc. Irvine, CA).  after minimisation 
using AM1 semi-empirical methods. 
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Figure and Scheme captions 
 
 
Figure 1: Structures of squaramide based amino acid receptors 1 – 8 highlighting the positions of 
NHA, NHB and NHC. 
 
Scheme 1: General synthetic approach to anion receptors 1 - 8;  (i) 20% v/v piperidine in DMF , (ii) 
carboxylic acid, HBTU, iPr2NEt, DMF, (iii) Pd(PPh3)4 , AcOH, morpholine, CHCl3, (iv) ethyl 
squarate monoamide, Et3N, EtOH, (v) TFA/H2O/triisopropylsilane (95:2.5:2.5 v/v), (vi) amine, 
EDC, iPr2NEt, CH2Cl2.   
 
Figure 2: Stack plots of 1H NMR spectra of  1 (2.5 × 10-3 M) upon addition of (a) (TBA)2SO4 and 
(b) TBAOAc (0  – 12 eq.) in 0.5% H2O in DMSO-d6 at 25 °C. (c) Comparison isotherms of 1 
(NHA) in the presence of increasing concentrations of SO42- (♦), Cl- (■), BzO- (▲) and AcO-(×) and 
(d) Comparison isotherms of 1 (NHC) in the presence of increasing concentrations of SO42- (♦), 
Cl- (■), BzO- (▲) and AcO-(×) 
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Figure 1 
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Scheme 1 
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Figure 2 
 
